Skyrizi On-Body (Risankizumab-Rzaa) — Medicare Part D spending
Abbvie US LLC · Rank #337 by total Part D spend · CMS data year 2023
Medicare Part D spent $125,306,777 on Skyrizi On-Body (Risankizumab-Rzaa) in 2023, the #337 drug by total Part D spending out of 3,598 drugs. That worked out to about $9,002.43 per dosage unit, $20,589 per claim and $69,499 per beneficiary, across 6,086 claims for 1,803 beneficiaries. Average spending per dosage unit rose +13.5% from 2022. These are aggregate Medicare program figures (gross drug cost), not the price you pay.
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Skyrizi On-Body (Risankizumab-Rzaa) spending at a glance (2023)
| Metric | Skyrizi On-Body (Risankizumab-Rzaa) |
|---|---|
| Total Part D spending (2023) | $125,306,777 |
| Total spending (2022) | $4,310,899 |
| Year-over-year change in total spending | +2806.7% |
| Average spending per dosage unit (2023) | $9,002.43 |
| Change in spend per dosage unit (YoY) | +13.5% |
| Avg annual change per dosage unit (2019-2023 CAGR) | +13.5% |
| Average spending per claim (2023) | $20,589 |
| Average spending per beneficiary (2023) | $69,499 |
| Total claims (2023) | 6,086 |
| Beneficiaries (2023) | 1,803 |
| Total dosage units (2023) | 14,249 |
| Manufacturer(s) | Abbvie US LLC |
| National rank by total spend (of 3,598 drugs) | #337 |
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
2022 vs 2023
| Metric | 2022 | 2023 | Change |
|---|---|---|---|
| Total spending | $4,310,899 | $125,306,777 | +2806.7% |
| Avg spend per dosage unit | $7,933.20 | $9,002.43 | +13.5% |
| Avg spend per claim | $18,991 | $20,589 | — |
| Avg spend per beneficiary | $23,949 | $69,499 | — |
| Total claims | 227 | 6,086 | — |
| Beneficiaries | 180 | 1,803 | — |
How Skyrizi On-Body compares with nearby drugs
Drugs with total Part D spending closest to Skyrizi On-Body (Risankizumab-Rzaa):
| Drug (rank) | Total spend 2023 | Per dosage unit | Per-unit YoY |
|---|---|---|---|
| Skyrizi On-Body (Risankizumab-Rzaa) (this drug, #337) | $125,306,777 | $9,002.43 | +13.5% |
| Nano 2nd Gen Pen Needle (Pen Needle, Diabetic) (#335) | $127,016,041 | $0.54 | +3.1% |
| Gilenya (Fingolimod HCl) (#336) | $125,490,483 | $356.52 | +6.4% |
| Carbidopa-Levodopa (Carbidopa/Levodopa) (#338) | $125,111,276 | $0.20 | -5.1% |
| Humulin 70/30 Kwikpen (Insulin NPh Hum/Reg Insulin Hm) (#339) | $124,346,168 | $25.46 | +0.4% |
| Iclusig (Ponatinib HCl) (#340) | $123,338,680 | $686.96 | +6.1% |
Frequently asked questions
How much does Medicare Part D spend on Skyrizi On-Body?
Medicare Part D spent $125,306,777 on Skyrizi On-Body (Risankizumab-Rzaa) in 2023 (the latest CMS data year), across 6,086 claims for 1,803 beneficiaries. That ranks #337 of 3,598 drugs by total Part D spending. This is gross drug cost (Medicare, plan and beneficiary payments combined), not the price you personally pay.
What is the average spending per dosage unit for Skyrizi On-Body?
In 2023, the weighted average Medicare Part D spending per dosage unit for Skyrizi On-Body (Risankizumab-Rzaa) was $9,002.43. Compared with 2022 it rose +13.5%. A "dosage unit" is one pill, tablet, milliliter or other billing unit, so this is not the price of a prescription.
Who makes Skyrizi On-Body?
CMS attributes Skyrizi On-Body (Risankizumab-Rzaa) to Abbvie US LLC in the 2023 Part D spending file. Average spending per claim was $20,589 and per beneficiary $69,499.
Is the Skyrizi On-Body figure the price I pay?
No. These are aggregate Medicare Part D program figures (total gross drug cost and averages across all claims), published by CMS for transparency. Your out-of-pocket cost depends on your plan, formulary, deductible and coverage phase. Always check your plan and talk to your pharmacist or doctor.
Keep exploring
Source & what this means
Figures are from the CMS Medicare Part D Spending by Drug dataset (data year 2023, US public domain). "Total spending" is the gross drug cost — Medicare, plan and beneficiary payments combined — for Part D claims; it is not a list price, a negotiated price, or what any individual pays. Spending per dosage unit is volume-weighted across formulations. This is general public-spending information, not medical or pricing advice. Your own cost depends on your plan, deductible and coverage phase — verify with your Part D plan and a pharmacist. Data as of June 2026. See our methodology and disclaimer.
Last updated: 2026-06-20